Qiagen (0RLT) Share Price & Analysis
0RLT Stock Chart & Stats
- Day’s Range
- EUR 45.02 - EUR 45.17
- 52-Week Range
- EUR 27.66 - EUR 47.60
- Previous Close
- EUR 45.09
- Volume
- 122.05K
- Average Volume (3M)
- 530.34K
- Market Cap
- EUR 9.29B
- Enterprise Value
- EUR 8.98B
- Total Cash (Recent Filing)
- EUR 793.50M
- Total Debt (Recent Filing)
- EUR 1.64B
- Price to Earnings (P/E)
- 25.8
- Beta
- 0.44
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- 0.56
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 5.19%
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Model
QIAGEN's recurring consumables and reagent sales are tied to ongoing laboratory testing and research activity, giving the business a replenishment component beyond episodic instrument purchases. This supports revenue durability, customer workflow integration, and future pull-through for compatible platforms.
Strong Profitability
High gross and operating margins indicate that QIAGEN's established products and workflows retain meaningful economic value after development and operating costs. If broadly sustained, this profitability provides capacity to fund innovation, absorb moderate demand pressure, and support shareholder returns.
Product And Growth-Pillar Momentum
Growth across Sample Technologies, QIAcuity, and digital insights, alongside launches such as QIAsymphony Connect and QIAmini, broadens QIAGEN's platform footprint. Greater workflow adoption can expand consumable pull-through and reduce reliance on any single diagnostic category.
Bears Say
Takeover And Governance Uncertainty
The planned transaction introduces execution, regulatory, and governance uncertainty over the next several months, including possible delays, legal challenges, and business disruption. Changes in ownership, board composition, and public-market status could also alter capital allocation and strategic priorities.
Uneven End-Market Demand
Weakness in QIAstat, PCR-related products, China, and parts of EMEA shows that demand is uneven across important businesses and geographies. Persistent softness could offset growth in better-performing pillars, slow operating leverage, and make consolidated growth dependent on a narrower set of products.
Volatile Cash Conversion
Although recent operating and free cash flow are strong, historical conversion has varied materially and free-cash-flow growth has been inconsistent. Such swings can reflect changing working-capital demands and may reduce predictability when QIAGEN is funding launches, restructuring, or capital returns.
Qiagen News
0RLT FAQ
What was Qiagen’s price range in the past 12 months?
What is Qiagen’s market cap?
When is Qiagen’s upcoming earnings report date?
How were Qiagen’s earnings last quarter?
Is Qiagen overvalued?
Does Qiagen pay dividends?
What is Qiagen’s EPS estimate?
How many shares outstanding does Qiagen have?
What happened to Qiagen’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Qiagen?
What is the TipRanks Smart Score and how is it calculated?
Qiagen Stock Smart Score
Company Description
Qiagen
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Jon Pratt
- Employees
- 5,500
- Website
- www.qiagen.com
- Address
- Hulsterweg 82, Venlo, LI, 5912 PL, NL
Qiagen (0RLT) Earnings & Revenues
0RLT Company Deck
0RLT Earnings Call
Earnings Call SentimentPositive
The call was broadly positive: management reported results above outlook for sales and adjusted EPS, strong cash generation, high profitability, and clear momentum in key growth pillars (Sample Technologies, QIAcuity, QDI) alongside active product launches and capital returns (40% dividend increase, $500M repurchase). Challenges include declines in QIAstat and PCR product groups, China and regional softness, a notable revenue loss from reduced immigration testing (~$35M) affecting QuantiFERON comparisons, modest margin and inventory pressures, and ongoing strategic/leadership transition that creates near-term uncertainty. On balance, the company emphasized confidence in a stronger second half of 2026 driven by new product rollouts and easing comparables.
View all GB:0RLT earnings summaries0RLT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 3 | 6 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 11 | 0 | 1 |
